Barcelona , Spain (ots/PRNewswire) - - The phase IV study TRIBUTE demonstrated that tildrakizumab is the first and only IL-23p19 inhibitor to improve sleep impairment in psoriasis patients after 24 weeks of treatment in conditions close to clinical practice1 - Patients also reported significant improvement in ...
Barcelona, Spain (ots/PRNewswire) - - New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity - Results suggest less frequent, every four week dosing of lebrikizumab provided ...
Barcelona, Spain (ots/PRNewswire) - - Strong operational performance during the first half of the year. The business continues to perform well boosted by the growth in Core Net Sales (+5.1% year-on-year) from key products of the Medical Dermatology portfolio - The EU Dermatology portfolio continues to lead the growth of Almirall's business. Ilumetri® maintained an ...
